GlaxoSmithKline/£GSK
08:00
10:10
12:15
14:25
16:30
1D1W1MYTD1Y5YMAX
About GlaxoSmithKline
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Ticker
£GSK
Sector
Primary listing
LSE
Employees
68,629
Headquarters
Website
GlaxoSmithKline Metrics
BasicAdvanced
£72B
13.41
£1.33
0.29
£0.63
3.54%
Price and volume
Market cap
£72B
Beta
0.29
52-week high
£17.94
52-week low
£12.43
Average daily volume
9.1M
Dividend rate
£0.63
Financial strength
Current ratio
0.836
Quick ratio
0.544
Long term debt to equity
94.553
Total debt to equity
112.684
Dividend payout ratio (TTM)
46.05%
Interest coverage (TTM)
10.96%
Profitability
EBITDA (TTM)
9,519
Gross margin (TTM)
72.43%
Net profit margin (TTM)
17.08%
Operating margin (TTM)
21.17%
Effective tax rate (TTM)
13.56%
Revenue per employee (TTM)
£470,000
Management effectiveness
Return on assets (TTM)
7.13%
Return on equity (TTM)
41.52%
Valuation
Price to earnings (TTM)
13.412
Price to revenue (TTM)
2.253
Price to book
4.12
Price to tangible book (TTM)
-8.49
Price to free cash flow (TTM)
15.053
Free cash flow yield (TTM)
6.64%
Free cash flow per share (TTM)
1.184
Dividend yield (TTM)
3.54%
Growth
Revenue change (TTM)
2.73%
Earnings per share change (TTM)
118.57%
3-year revenue growth (CAGR)
3.49%
10-year revenue growth (CAGR)
3.05%
3-year earnings per share growth (CAGR)
-27.49%
10-year earnings per share growth (CAGR)
-6.22%
3-year dividend per share growth (CAGR)
-5.67%
10-year dividend per share growth (CAGR)
-4.36%
What the Analysts think about GlaxoSmithKline
Analyst ratings (Buy, Hold, Sell) for GlaxoSmithKline stock.
Bulls say / Bears say
GSK’s Q2 2025 results outperformed expectations, posting a 6% annual increase in turnover to nearly £8 billion and adjusted earnings of 46.5 pence per share, leading the company to project full-year sales and profit at the upper end of its guidance (Reuters).
The company secured a $500 million licensing agreement with China’s Jiangsu Hengrui Pharmaceuticals for worldwide rights to HRS-9821 and 11 early-stage programs, potentially adding promising COPD, cancer, immunology, and inflammation candidates to GSK’s R&D pipeline (Reuters).
The UK’s NICE issued a favorable recommendation for ViiV Healthcare’s long-acting HIV prevention treatment Apretude, allowing standard NHS funding and patient access in England and Wales, which could strengthen GSK’s HIV market position in a key region (Reuters).
GSK’s vaccine business is facing challenges, with Q1 2025 sales of its RSV vaccine Arexvy dropping 57% to £78 million, significantly missing forecasts and highlighting reduced demand in a key area for growth (Reuters).
The company’s outlook and profit margins are under pressure from planned 15% tariffs on European pharmaceutical exports as part of the new US-EU trade agreement, and these impacts are already included in its 2025 projections (Reuters).
ViiV Healthcare widened its voluntary license to allow generic versions of long-acting injectable cabotegravir in 133 countries, which could undermine GSK’s pricing and future margins in its fast-growing HIV division (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2025.
GlaxoSmithKline Financial Performance
Revenues and expenses
GlaxoSmithKline Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for GlaxoSmithKline stock?
GlaxoSmithKline (GSK) has a market cap of £72B as of November 03, 2025.
What is the P/E ratio for GlaxoSmithKline stock?
The price to earnings (P/E) ratio for GlaxoSmithKline (GSK) stock is 13.41 as of November 03, 2025.
Does GlaxoSmithKline stock pay dividends?
Yes, the GlaxoSmithKline (GSK) stock pays dividends to shareholders. As of November 03, 2025, the dividend rate is £0.63 and the yield is 3.54%. GlaxoSmithKline has a payout ratio of 46.05% on a trailing twelve-month basis.
When is the next GlaxoSmithKline dividend payment date?
The next GlaxoSmithKline (GSK) dividend payment is scheduled for January 08, 2026.
What is the beta indicator for GlaxoSmithKline?
GlaxoSmithKline (GSK) has a beta rating of 0.29. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.